10 June 2021
Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders
3 May 2021
Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related α-synucleopathies at the XXVI IAPRD World Congress
18 March 2021
Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock
4 February 2021
Gain Therapeutics Announces Three Late-Breaker Presentations at the 17th Annual WORLDSymposium
10 September 2020
Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program
21 July 2020
Financing intended to accelerate IND-enabling studies of allosteric drug candidates for rare genetic and neurodegenerative diseases, expand pipeline and support business development activities
19 February 2019
Luxembourg, February 19, 2019: Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient need, today announces that it has made a €1 Million investment in Gain Therapeutics SA.
Thank you for your form submission, we will get in contact with you shortly.